CDC says it will update U.S. childhood immunization schedule after presidential review directive
The CDC announced it has accepted recommendations to update the U.S. childhood immunization schedule following a presidential memorandum directing a review of how peer countries structure their vaccine guidance.
The Centers for Disease Control and Prevention (CDC) said it will move forward with changes to the U.S. childhood immunization schedule after accepting recommendations produced by a comprehensive scientific assessment. The announcement, dated January 5, 2026, followed a presidential memorandum issued on December 5, 2025 directing federal health agencies to compare U.S. practices with those of peer, developed nations and to update the schedule if better approaches were identified.
In its release, the CDC described a revised framework that continues to present immunization guidance across three categories: vaccines recommended for all children, vaccines recommended for certain high-risk groups or populations, and vaccines offered based on shared clinical decision-making. The agency emphasized that the categories are structured so insurers continue to cover vaccines without cost-sharing.
The CDC listed a set of vaccines that remain in the “recommended for all children” grouping, including those for measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Hib, pneumococcal disease, HPV, and varicella. Officials said the approach is intended to align U.S. practice with international consensus while also emphasizing transparency and informed consent.
The release also cited a documented decline in public trust in health institutions between 2020 and 2024 and noted concern about falling childhood vaccination rates and the associated risk of vaccine-preventable disease. In that context, federal health leaders framed the update as part of a broader effort to rebuild confidence while maintaining protection against serious illness.
Public health groups are likely to scrutinize the practical implications of the “shared clinical decision-making” category, which can shape how clinicians counsel families and how schools and states interpret vaccine guidance. Supporters argue it encourages individualized care; critics warn it could introduce confusion and weaken uptake if messaging becomes inconsistent.
For families, the CDC’s central assurance was about access and affordability: the agency stated vaccines currently recommended will remain covered by insurance without cost-sharing. The next stage will involve implementation details, updates to clinical materials, and communication to pediatric providers—steps that will determine how the changes are understood and applied across the country.